Title:
BIOMARKER-BASED THERAPEUTIC COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2021/045279
Kind Code:
A1
Abstract:
The present invention provides an anticancer drug for treating patients resistant to protein kinase, the drug comprising a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof as an active ingredient. Here, the patients may be patients with an active RON. In addition, the patient may be patients with a normal KRAS. In addition, the anticancer drug can be applied to patients who have resistance to EGFR inhibitors. In particular, the anticancer drug can be effectively used for treating patients who are resistant to cetuximab treatment.
More Like This:
Inventors:
HONG SEUNG-WOO (KR)
MOON JAI-HEE (KR)
SHIN JAE-SIK (KR)
KIM JOSEPH (KR)
PARK YOON-SUN (KR)
LEE MIN-KI (KR)
JEONG JOON-YEE (KR)
LEE SO-HEE (KR)
CHOI SOON-JIN (KR)
MOON JAI-HEE (KR)
SHIN JAE-SIK (KR)
KIM JOSEPH (KR)
PARK YOON-SUN (KR)
LEE MIN-KI (KR)
JEONG JOON-YEE (KR)
LEE SO-HEE (KR)
CHOI SOON-JIN (KR)
Application Number:
PCT/KR2019/011570
Publication Date:
March 11, 2021
Filing Date:
September 06, 2019
Export Citation:
Assignee:
WELLMARKER BIO CO LTD (KR)
International Classes:
C07D495/04; A61K31/4365; A61P35/00; C07K16/28
Domestic Patent References:
| WO2012167600A1 | 2012-12-13 | |||
| WO2009026717A1 | 2009-03-05 | |||
| WO2009026717A1 | 2009-03-05 |
Foreign References:
| KR20160028399A | 2016-03-11 | |||
| KR101350006B1 | 2014-02-13 | |||
| US20070197537A1 | 2007-08-23 | |||
| US8536200B2 | 2013-09-17 | |||
| US8088794B2 | 2012-01-03 | |||
| US8030302B2 | 2011-10-04 |
Other References:
See also references of EP 3819300A4
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: